$BCAX
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Healthcare
Sector
Biotechnology
Industry
Ryan Cohlhepp
CEO
55
Employees
$18.41
Current Price
$896.78M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 5 | $528,079.44 | 27,500 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 6 | $1,232,736.60 | 64,266 | ||
| 1 month | Buys | 1 | 1 | $4,800,000.00 | 300,000 | 2.02:1 |
| Sells | 4 | 17 | $2,375,036.66 | 126,541 | ||
| 2 months | Buys | 1 | 1 | $4,800,000.00 | 300,000 | 1.94:1 |
| Sells | 4 | 19 | $2,478,495.09 | 132,251 | ||
| 3 months | Buys | 1 | 1 | $4,800,000.00 | 300,000 | 1.93:1 |
| Sells | 4 | 20 | $2,481,180.07 | 132,400 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 18, 2026 | Mazumdar Claire Director | Sale | 6,499 | $18.84 | $122,414.51 | View Details |
| Mar 19, 2026 | Mazumdar Claire Director | Sale | 6,905 | $18.78 | $129,704.90 | View Details |
| Mar 20, 2026 | Mazumdar Claire Director | Sale | 1,596 | $18.95 | $30,246.27 | View Details |
| Mar 16, 2026 | Cohlhepp Ryan Director | Sale | 8,000 | $19.66 | $157,256.80 | View Details |
| Mar 16, 2026 | Cohlhepp Ryan Director | Sale | 4,500 | $19.66 | $88,456.95 | View Details |
| Mar 9, 2026 | Mazumdar Claire Director | Sale | 36,766 | $19.17 | $704,657.16 | View Details |
| Mar 4, 2026 | Mazumdar Claire Director | Sale | 2,631 | $18.73 | $49,288.63 | View Details |
| Mar 5, 2026 | Mazumdar Claire Director | Sale | 1,786 | $18.74 | $33,464.10 | View Details |
| Mar 6, 2026 | Mazumdar Claire Director | Sale | 3,817 | $18.75 | $71,571.80 | View Details |
| Mar 3, 2026 | Cohlhepp Ryan Director | Sale | 12,892 | $18.16 | $234,158.69 | View Details |
| Mar 3, 2026 | Cohlhepp Ryan Director | Sale | 4,500 | $18.16 | $81,733.95 | View Details |
| Mar 3, 2026 | Hyep Ivan Chief Financial Officer | Sale | 13,555 | $18.22 | $246,909.75 | View Details |
| Mar 4, 2026 | Hyep Ivan Chief Financial Officer | Sale | 2,963 | $18.25 | $54,061.71 | View Details |
| Mar 3, 2026 | Raben David Chief Medical Officer | Sale | 200 | $18.45 | $3,690.00 | View Details |
| Mar 4, 2026 | Raben David Chief Medical Officer | Sale | 16,300 | $18.52 | $301,920.01 | View Details |
| Feb 26, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | 2,200,000 | $16.00 | $35,199,780.00 | View Details |
| Feb 26, 2026 | RA CAPITAL MANAGEMENT, L.P. Director | Purchase | 300,000 | $16.00 | $4,800,000.00 | View Details |
| Feb 25, 2026 | Cohlhepp Ryan Director | Sale | 3,108 | $18.04 | $56,066.77 | View Details |
| Feb 25, 2026 | Cohlhepp Ryan Director | Sale | 523 | $18.04 | $9,434.66 | View Details |
| Jan 22, 2026 | Cohlhepp Ryan Director | Sale | 3,828 | $18.10 | $69,295.99 | View Details |
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$0.67
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$CDTX โ Cidara Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$WVE โ Wave Life Sciences Ltd.via RA CAPITAL MANAGEMENT, L.P.$CLYM โ Climb Bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$SGP โ SpyGlass Pharma, Inc. Common Stockvia RA CAPITAL MANAGEMENT, L.P.$HOWL โ Werewolf Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$PEPG โ PepGen Inc.via RA CAPITAL MANAGEMENT, L.P.$TYRA โ Tyra Biosciences, Inc.via RA CAPITAL MANAGEMENT, L.P.$MLYS โ Mineralys Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.